Morgan Stanley downgrades Erasca stock to Equalweight on delayed clinical data

Morgan Stanley downgraded Erasca Inc (ERAS) to Equalweight with a $2.00 price target, from Overweight and $4.00, primarily citing an extended timeline for key clinical data, with initial results for its ERAS-0015 and ERAS-4001 compounds not anticipated until 2026. Despite recent FDA Investigational New Drug (IND) clearances for these cancer therapies, the downgrade reflects concerns over the company's significant cash burn and the prolonged wait for clinical clarity, leading Morgan Stanley to seek better opportunities despite acknowledging Erasca's scientific merit. The stock has seen a nearly 35% year-to-date decline.

Analysis

Morgan Stanley has downgraded Erasca Inc. (ERAS) to Equalweight from Overweight and cut its price target by 50% to $2.00, reflecting significant concerns over delayed clinical data timelines. The core issue is that initial results for the company's key pipeline assets, ERAS-0015 and ERAS-4001, are not anticipated until 2026, creating a prolonged period of uncertainty for investors. This ratings change occurs despite recent positive regulatory momentum, including the U.S. FDA's clearance of Investigational New Drug (IND) applications for both therapies, which target a large market of KRAS-mutant tumors. While Erasca projects its cash runway extends into the second half of 2028 and holds more cash than debt, the firm is noted to be burning through cash rapidly. This financial pressure, combined with the lack of near-term data catalysts and a strategic pivot to seek partners for naporafenib, has led Morgan Stanley to conclude that better opportunities exist elsewhere until Erasca provides greater clarity on the clinical and commercial path for its assets, even while acknowledging their scientific potential.

Key Decisions for Investors

• Given the downgrade and lack of clinical catalysts until 2026, investors should anticipate continued share price pressure and limited near-term upside, warranting a re-evaluation of positions in light of the stock's 35% year-to-date decline.
• Prospective investors must weigh the long-term potential of Erasca's first-in-class oncology pipeline against the significant risks of a high cash burn rate and a multi-year wait for pivotal data.
• Monitor the company's quarterly cash consumption closely relative to its stated H2 2028 runway, as any acceleration in burn rate could necessitate future financing and further dilute shareholder value before key data readouts.
• Any news regarding a partnership for the naporafenib program should be viewed as a key potential catalyst, as it could provide non-dilutive capital and third-party validation of the company's platform.